US 12,453,734 B2
Modulators of rho-associated protein kinase
Clifford D. Jones, Macclesfield (GB); Peter Bunyard, Macclesfield (GB); Gary Pitt, Macclesfield (GB); Liam Byrne, Macclesfield (GB); Thomas Pesnot, Chester (GB); and Nicolas E. S. Guisot, Macclesfield (GB)
Assigned to Redx Pharma Limited, Macclesfield (GB)
Filed by Redx Pharma Limited, Macclesfield (GB)
Filed on Dec. 8, 2023, as Appl. No. 18/534,285.
Application 18/534,285 is a continuation of application No. 17/896,626, filed on Aug. 26, 2022, granted, now 11,878,020, issued on Jan. 23, 2024.
Application 17/896,626 is a continuation of application No. 16/964,904, granted, now 11,497,751, issued on Nov. 15, 2022, previously published as PCT/GB2019/050215, filed on Jan. 25, 2019.
Claims priority of application No. 1801226 (GB), filed on Jan. 25, 2018.
Prior Publication US 2024/0216386 A1, Jul. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/538 (2006.01); A61K 31/4196 (2006.01); A61K 31/5377 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01)
CPC A61K 31/538 (2013.01) [A61K 31/4196 (2013.01); A61K 31/5377 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01)] 10 Claims
 
1. A compound, wherein the compound is:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.